Ontology highlight
ABSTRACT: Background
Current predictive model is not developed by inflammation-related genes to evaluate clinical outcome of breast cancer patients.Methods
With mRNA expression profiling, we identified 3 mRNAs with significant expression between 15 normal samples and 669 breast cancer patients. Using 7 cell lines and 150 paraffin-embedded specimens, we verified the expression pattern by bio-experiments. Then, we constructed a three-mRNA model by Cox regression method and approved its predictive accuracy in both training set (n = 1095) and 4 testing sets (n = 703).Results
We developed a three-mRNA (TBX21, TGIF2, and CYCS) model to stratify patients into high- and low-risk subgroup with significantly different prognosis. In training set, 5-year OS rate was 84.5% (78.8%-90.5%) vs 73.1% (65.9%-81.2%) for the low- and high-risk group (HR = 1.573 (1.090-2.271); P = 0.016). The predictive value was similar in four independent testing sets (HR>1.600; P < 0.05). This model could assess survival independently with better predictive power compared with single clinicopathological risk factors and any of the three mRNAs. Patients with both low-risk values and any poor prognostic factors had more favorable survival from nonmetastatic status (HR = 1.740 (1.028-2.945), P = 0.039). We established two nomograms for clinical application that integrated this model and another three significant risk factors to forecast survival rates precisely in patients with or without metastasis.Conclusions
This model is a dependable tool to predict the disease recurrence precisely and could improve the predictive accuracy of survival probability for breast cancer patients with or without metastasis.
SUBMITTER: Zhao S
PROVIDER: S-EPMC6382731 | biostudies-literature | 2019 Feb
REPOSITORIES: biostudies-literature
Zhao Shuangtao S Shen Wenzhi W Du Renle R Luo Xiaohe X Yu Jiangyong J Zhou Wei W Dong Xiaoli X Gao Ruifang R Wang Chaobin C Yang Houpu H Wang Shu S
Cancer medicine 20190111 2
<h4>Background</h4>Current predictive model is not developed by inflammation-related genes to evaluate clinical outcome of breast cancer patients.<h4>Methods</h4>With mRNA expression profiling, we identified 3 mRNAs with significant expression between 15 normal samples and 669 breast cancer patients. Using 7 cell lines and 150 paraffin-embedded specimens, we verified the expression pattern by bio-experiments. Then, we constructed a three-mRNA model by Cox regression method and approved its predi ...[more]